The cost-effectiveness of rosuvastatin and atorvastatin in the primary prevention of cardiovascular disease based on the discovery-belux study.

M. Lamotte; Lieven Annemans; Mc. Herregods; Jean-Claude Daubresse; G. Michel; G. Vandenhoven; E. Vissers

The cost-effectiveness of rosuvastatin and atorvastatin in the primary prevention of cardiovascular disease based on the discovery-belux study.

M. Lamotte
, Lieven Annemans
, Mc. Herregods
, Jean-Claude Daubresse
, G. Michel
, G. Vandenhoven
, E. Vissers

Biomechanics and Human Biometry

Research output: Contribution to journal › Article › peer-review

Abstract

/

Original language	English
Pages (from-to)	61
Number of pages	1
Journal	European Journal of Cardiovascular Prevention & Rehabilitation
Volume	13
Publication status	Published - 2006

Keywords

Cardiovascular disease

Handle.net

Persistent link

Cite this

@article{3dc73e513766453490f6558bfeaa2dad,

title = "The cost-effectiveness of rosuvastatin and atorvastatin in the primary prevention of cardiovascular disease based on the discovery-belux study.",

abstract = "/",

keywords = "Cardiovascular disease",

author = "M. Lamotte and Lieven Annemans and Mc. Herregods and Jean-Claude Daubresse and G. Michel and G. Vandenhoven and E. Vissers",

year = "2006",

language = "English",

volume = "13",

pages = "61",

journal = "European Journal of Cardiovascular Prevention \& Rehabilitation",

issn = "1741-8267",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - The cost-effectiveness of rosuvastatin and atorvastatin in the primary prevention of cardiovascular disease based on the discovery-belux study.

AU - Lamotte, M.

AU - Annemans, Lieven

AU - Herregods, Mc.

AU - Daubresse, Jean-Claude

AU - Michel, G.

AU - Vandenhoven, G.

AU - Vissers, E.

PY - 2006

Y1 - 2006

N2 - /

AB - /

KW - Cardiovascular disease

M3 - Article

SN - 1741-8267

VL - 13

SP - 61

JO - European Journal of Cardiovascular Prevention & Rehabilitation

JF - European Journal of Cardiovascular Prevention & Rehabilitation

ER -

The cost-effectiveness of rosuvastatin and atorvastatin in the primary prevention of cardiovascular disease based on the discovery-belux study.

Abstract

Keywords

Handle.net

Fingerprint

Cite this